- Use Cases
PALO ALTO, Calif. and TORONTO, September 3, 2020 /PRNewswire/ -- Inpixon® (Nasdaq: INPX), a leading indoor data company that delivers Indoor Intelligence™ solutions, today announced that it has executed contracts to deploy its Indoor Intelligence solutions for Privée Clinics' flagship cognitive wellness clinic located in the atrium of the Conrad, Miami, hotel. The contracted solution includes Inpixon Pod Wi-Fi sensors, Inpixon Workplace Readiness Dashboards and Inpixon Mapping with the installation to be completed prior to the November 16, 2020, clinic grand opening.
Privée Clinics will offer personalized, high-end wellness services intended to enhance cognitive performance and physical health and beauty as well as to reduce stress, improve sleep and boost immunity against viral infections such as COVID-19. By decreasing the effects of stress on the brain through advanced technology oxygenation techniques and nutritional supplementation, Privée Clinics intends to help its clients slow the ageing process, particularly as it affects the brain. Privée Clinics was founded by the renowned Bankole Johnson, MD, founder and chief medical officer of Adial Pharmaceuticals.
Inpixon’s Mapping and near real-time analytics will help Privée Clinics with their efforts to provide world-class service to their clientele by showing trends and changes in people flow and density by zones using device positioning and dwell times. Inpixon’s Workplace Readiness dashboard will provide a comprehensive viewpoint of the facility that can assist the doctors and staff members with a dynamic, multidimensional map of the clinic, including key insights on zone health based on area occupancy density, to support new safety protocols and regulations, along with the flexibility to address future indoor location-based use cases.
“Privée Clinics is delighted to implement Inpixon Indoor Intelligence technologies into our clinics to create what we believe is the world’s first anti-COVID-19 model clinic system,” commented Dr. Johnson, Founder, Executive Chairman and CEO of Privée Clinics. “As a leading physician, I was impressed by the capabilities of Inpixon's offering and the fact they are already trusted by many notable healthcare facilities, commercial enterprises and the U.S. government. Inpixon’s technology will assist with efficient client processing through the clinic and rapid decontamination of areas that need it most, delivering a safer, tailored and world-class approach to bespoke health care.”
“Inpixon is excited to be included as a fundamental element of the new Privée Clinics offering,” said Soumya Das, COO of Inpixon. “They are striving to establish a new standard of care during this pandemic situation and beyond, and setting a high bar for all doctors’ offices and clinics to follow. We're proud to play such an integral role in this important endeavor.”
Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™ company that specializes in capturing, interpreting and giving context to indoor data so it can be translated into actionable intelligence. The company’s Indoor Intelligence platform ingests diverse data from IoT, third-party and proprietary sensors designed to detect and position active cellular, Wi-Fi, UWB and Bluetooth devices. Paired with a high-performance data analytics engine, patented algorithms, and advanced mapping technology, Inpixon’s solutions are leveraged by a multitude of industries to do good with indoor data. This multidisciplinary depiction of indoor data enables users to increase revenue, decrease costs, and enhance safety. Inpixon customers can boldly take advantage of location awareness, analytics, sensor fusion and the Internet of Things (IoT) to uncover the untold stories of the indoors. For the latest insights, follow Inpixon on LinkedIn, Twitter, and visit inpixon.com.
Safe Harbor Statement
All statements in this release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19 on Inpixon's results of operations, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Inpixon’s technology, Inpixon's ability to maintain compliance with Nasdaq’s minimum bid price requirement and other continued listing requirements, including during a panel monitoring period ending on February 5, 2021, the ability to obtain financing, competition, general economic conditions and other factors that are detailed in Inpixon's periodic and current reports available for review at sec.gov. Furthermore, Inpixon operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Inpixon disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.
Crescendo Communications, LLC
Tel: +1 212-671-1020